REPL · Insider Trading
Replimune Group, Inc.
Every open-market purchase and sale reported by REPL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | Philip Astley-Sparke | Director | G | −50,000 | — |
| 2026-08-19 | Emily Luisa Hill | Chief Financial Officer | Sell | −9,256 | −$132.18K |
| 2026-08-12 | Andrew Schwendenman | Chief Accounting Officer | Sell | −7,632 | −$98.99K |
| 2026-08-12 | Emily Luisa Hill | Chief Financial Officer | Sell | −11,448 | −$148.48K |
| 2026-08-12 | Konstantinos Xynos | Chief Medical Officer | Sell | −11,447 | −$148.47K |
| 2026-08-12 | Sushil Patel | Chief Executive Officer | Sell | −39,341 | −$510.25K |
| 2026-08-11 | Julian Baker | Director | Buy | +16,418,040 deriv. | — |
| 2026-06-03 | Christopher Sarchi | Chief Commercial Officer | Sell | −12,000 | −$110.88K |
| 2026-05-20 | Andrew Schwendenman | Chief Accounting Officer | Sell | −7,894 | −$40.10K |
| 2026-05-20 | Sushil Patel | Chief Executive Officer | Sell | −37,324 | −$189.61K |
| 2026-05-20 | Emily Luisa Hill | Chief Financial Officer | Sell | −7,812 | −$39.68K |
| 2026-05-20 | Christopher Sarchi | Chief Commercial Officer | Sell | −8,626 | −$43.82K |
| 2026-05-20 | Konstantinos Xynos | Chief Medical Officer | Sell | −14,023 | −$71.24K |
| 2026-05-20 | Philip Astley-Sparke | Director | Sell | −17,657 | −$89.70K |
| 2026-04-07 | Christopher Sarchi | Chief Commercial Officer | A | +50,000 | — |
| 2026-04-07 | Kapil Dhingra | Director | A | +44,500 deriv. | — |
| 2026-04-07 | Veleka Peeples-Dyer | Director | A | +44,500 deriv. | — |
| 2026-04-07 | Dieter Weinand | Director | A | +44,500 deriv. | — |
| 2026-04-07 | Paolo Pucci | Director | A | +44,500 deriv. | — |
| 2026-04-07 | Philip Astley-Sparke | Director | A | +50,000 | — |
| 2026-04-07 | Andrew Schwendenman | Chief Accounting Officer | A | −36,667 | — |
| 2026-04-07 | Christy J. Oliger | Director | A | +44,500 deriv. | — |
| 2026-04-07 | Konstantinos Xynos | Chief Medical Officer | A | +50,000 | — |
| 2026-04-07 | Madhavan Balachandran | Director | A | +44,500 deriv. | — |
| 2026-04-07 | 667, L.P. | Director | A | +534,000 deriv. | — |
| 2026-04-07 | Emily Luisa Hill | Chief Financial Officer | A | +50,000 | — |
| 2026-04-07 | Sushil Patel | Chief Executive Officer | A | +251,240 | — |
| 2026-04-07 | Joseph P Slattery | Director | A | +44,500 deriv. | — |
| 2026-04-06 | Christopher Sarchi | Chief Commercial Officer | Sell | −6,500 | −$52.06K |
| 2026-02-20 | Philip Astley-Sparke | Director | G | −25,000 | — |
| 2025-12-19 | Andrew Schwendenman | Chief Accounting Officer | A | +10,000 | — |
| 2025-12-19 | Christopher Sarchi | Chief Commercial Officer | A | +35,000 | — |
| 2025-12-19 | Sushil Patel | Chief Executive Officer | A | +200,000 | — |
| 2025-12-19 | Emily Luisa Hill | Chief Financial Officer | A | +60,000 | — |
| 2025-12-19 | Konstantinos Xynos | Chief Medical Officer | A | +60,000 | — |
| 2025-12-11 | Kapil Dhingra | Director | MIXED | — | −$27.41K |
| 2025-12-04 | Sushil Patel | Chief Executive Officer | Sell | −10,000 | −$111.30K |
| 2025-11-19 | Christopher Sarchi | Chief Commercial Officer | Sell | −5,208 | −$47.39K |
| 2025-11-19 | Konstantinos Xynos | Chief Medical Officer | Sell | −7,248 | −$65.96K |
| 2025-08-19 | Emily Luisa Hill | Chief Financial Officer | Sell | −9,154 | −$49.16K |
| 2025-05-22 | Konstantinos Xynos | Chief Medical Officer | Sell | −7,952 | −$64.09K |
| 2025-05-22 | Philip Astley-Sparke | Director | Sell | −32,279 | −$260.17K |
| 2025-05-22 | Emily Luisa Hill | Chief Financial Officer | Sell | −2,535 | −$20.41K |
| 2025-05-22 | Sushil Patel | Chief Executive Officer | Sell | −25,105 | −$202.35K |
| 2025-05-22 | Christopher Sarchi | Chief Commercial Officer | Sell | −3,749 | −$30.18K |
| 2025-05-22 | Andrew Schwendenman | Chief Accounting Officer | Sell | −3,287 | −$26.46K |
| 2025-04-03 | Joseph P Slattery | Director | A | +32,000 deriv. | — |
| 2025-04-03 | Emily Luisa Hill | Chief Financial Officer | A | +45,000 | — |
| 2025-04-03 | Madhavan Balachandran | Director | A | +32,000 deriv. | — |
| 2025-04-03 | Konstantinos Xynos | Chief Medical Officer | A | +45,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Philip Astley-Sparke | Director | 1,362,414 | $16.34M |
| Sushil Patel | Chief Executive Officer | 708,151 | $8.49M |
| Konstantinos Xynos | Chief Medical Officer | 224,215 | $2.69M |
| Emily Luisa Hill | Chief Financial Officer | 215,852 | $2.59M |
| Christopher Sarchi | Chief Commercial Officer | 180,962 | $2.17M |
| Andrew Schwendenman | Chief Accounting Officer | 99,425 | $1.19M |
| Joseph P Slattery | Director | 11,867 | $142.29K |
| Kapil Dhingra | Director | 3,169 | $38.00K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the REPL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.